Free Stock & ETF Comparisons

Compare CVS Health and Cigna by pharmacy benefits management market share, integrated care model, Evernorth vs Oak Street revenue, margin recovery trajectory, and which health services company offers better long-term value.

Compare HCA Healthcare and Universal Health Services by hospital vs behavioral health network, reimbursement rate trends, volume growth, operating leverage, and which hospital operator offers better margin expansion potential.

Compare Accenture and CGI Group by consulting vs managed IT services mix, federal government contract exposure, AI-driven services growth, operating margin, and which IT services company offers better long-term compounding.

Compare Baxter and Becton Dickinson by portfolio restructuring progress, IV solutions vs diagnostics revenue, hospital supply chain positioning, debt reduction pace, and which medical supply company offers better recovery upside.

Compare Thermo Fisher Scientific and West Pharmaceutical Services by bioproduction revenue, drug delivery component growth, biopharma customer concentration, margin profile, and which life science services company offers better value.

Compare McKesson and Cardinal Health by pharmaceutical distribution market share, specialty pharmacy growth, oncology services network, operating efficiency, and which drug wholesaler offers better long-term margin expansion.

Compare IQVIA and Medpace by full-service vs niche CRO positioning, biotech vs pharma customer concentration, EBITDA margin structure, backlog coverage ratio, and which clinical research company offers better risk-adjusted growth.

Compare Zimmer Biomet and Boston Scientific by orthopedic vs cardiovascular device market share, robotic surgery platform investment, international revenue mix, and which medical device company offers better long-term growth.

Compare Philips and Medtronic by imaging and patient monitoring vs cardiac rhythm management, recall resolution progress, software-enabled device strategy, international exposure, and long-term innovation pipeline.

Compare Abbott and DexCom by continuous glucose monitoring market share, Libre vs G7 sensor technology, non-diabetes CGM opportunity, device plus pharmaceutical portfolio diversification, and long-term diabetes care growth.

Compare GE HealthCare and Medtronic by medical imaging vs device revenue, AI diagnostic software investment, hospital vs outpatient channel mix, new product pipeline, and which healthcare equipment company offers better long-term upside.

Compare Gilead and Vertex by durable revenue moats, oncology and gene therapy pipeline depth, free cash flow generation, capital allocation, and which biotech compunder offers better long-term value.

Compare Moderna and Vertex by platform technology durability, COVID vaccine revenue decline vs CF monopoly stability, pipeline breadth, cash runway, and which biotech approach offers better long-term investment returns.

Compare AbbVie and Regeneron by post-Humira growth transition, Skyrizi and Rinvoq ramp, Dupixent label expansion, oncology pipeline, and which large-cap biotech offers better earnings visibility through 2030.

Compare Amgen and Regeneron by biosimilar exposure, GLP-1 obesity drug pipeline (MariTide), Dupixent vs Enbrel replacement, free cash flow, and which established biotech offers better risk-adjusted long-term returns.

Compare Biogen and Alnylam by Alzheimer's disease therapy validation, RNA interference platform breadth, pipeline conversion rate, revenue trajectory, and which biotech platform offers better long-term growth potential.

Compare Gilead and Moderna by revenue durability, pipeline diversification, cash generation vs cash burn, platform reinvestment, and which large biotech strategy — franchise cash flow or platform moonshot — offers better returns.

Compare Vertex Pharmaceuticals and BioMarin by rare disease franchise depth, gene therapy pipeline, pricing power, geographic expansion opportunity, and which rare disease biotech offers better long-term compounding.

Compare Ultragenyx and Biogen by rare disease pipeline breadth, commercialization risk, platform technology (gene vs antibody), pathway to profitability, and which biotech offers better near-term catalysts.

Compare Editas and Intellia Therapeutics by CRISPR vs base editing strategy, in vivo delivery progress, clinical pipeline advancement, partnership quality, and which gene editing company offers better long-term upside.

Compare Beam Therapeutics and Intellia by base editing vs CRISPR technology approach, clinical data readouts, cash runway, pipeline breadth, and which next-generation gene editing platform offers better investment potential.

Compare AbbVie and Roche ADR by oncology drug pipeline depth, post-patent cliff transition, HER2 and immunology franchises, dividend yield, and which large-cap pharma offers better defensive income with growth.

Compare Roche and Novartis ADRs by oncology vs cardiovascular drug leadership, diagnostics revenue mix, gene therapy pipeline investment, shareholder return programs, and which Swiss pharmaceutical giant offers better long-term value.

Compare PTC Therapeutics and BioMarin by Duchenne muscular dystrophy and PKU drug portfolios, regulatory pathway history, revenue growth trajectory, and which mid-cap rare disease biotech offers better risk-adjusted returns.

Compare Senseonics and DexCom by implantable Eversense vs wearable G7 sensor approach, user convenience tradeoffs, revenue scale, commercialization partner strategy, and long-term CGM market opportunity.

Compare Penumbra and Intuitive Surgical by neurovascular embolization vs multi-specialty robotic surgery markets, procedure volume growth, recurring capital vs consumable revenue, and long-term platform expansion.

Compare Novocure and Integra LifeSciences by tumor treating fields vs conventional neurosurgery device markets, revenue visibility, label expansion pipeline, margin structure, and which specialty medical device company offers better upside.

Compare BP and Shell ADRs by energy transition strategy ambition, LNG portfolio quality, downstream profitability, dividend safety after cuts, and which European integrated oil major offers better long-term income and upside.

Compare EOG and Occidental by Permian Basin acreage quality, production cost structure, Warren Buffett vote of confidence in OXY, carbon capture ambition, and which Permian-focused E&P is the better long-term investment.

Compare Devon Energy and APA Corp by Permian vs international production mix, free cash flow yield, variable dividend commitment, balance sheet strength, and which mid-cap upstream company offers better risk-adjusted energy exposure.

Compare Phillips 66 and Valero by refining throughput capacity, midstream and chemicals diversification, crack spread sensitivity, renewable diesel investment, and which downstream energy company offers better cycle exposure.

Compare Halliburton and Baker Hughes by completions market leadership, LNG equipment growth exposure, digital technology strategy, international revenue diversification, and which oilfield services company is better positioned.

Compare Enbridge and Energy Transfer by crude oil vs natural gas transmission revenue, utility-like regulatory framework, distribution yield safety, leverage, and which North American pipeline company offers better income value.

Compare Energy Transfer and Western Midstream by natural gas gathering and processing exposure, distribution growth trajectory, leverage reduction pace, Permian vs broader basin presence, and which MLP offers better yield and upside.

Compare Targa Resources and Energy Transfer by Permian Basin gas processing exposure, distribution growth policy, fee-based revenue quality, capital spending outlook, and which midstream company is better positioned for natural gas demand.

Compare NRG Energy and Constellation Energy by retail electricity vs nuclear power focus, AI data center power purchase agreement potential, renewable energy strategy, and which independent power producer offers better returns.

Compare GE Vernova and Vistra Energy by AI data center power demand exposure, grid modernization revenue vs generation capacity, backlog growth, margin structure, and which energy infrastructure company offers better near-term upside.

Compare Array Technologies and First Solar by solar supply chain position, US manufacturing exposure, tariff protection, revenue visibility via backlog, and which solar infrastructure company is better positioned for utility-scale solar growth.

Compare NextEra Energy and Atmos Energy by renewable energy vs natural gas distribution exposure, regulatory framework, earnings growth visibility, dividend yield, and which utility offers better defensive income and growth.

Compare Southern Company and Duke Energy by nuclear energy investment, clean energy transition pace, regulatory relationships, earnings per share growth guidance, and which integrated utility offers better income and stability.

Compare AEP and Exelon by transmission infrastructure investment, nuclear fleet leverage to power prices, distribution segment growth, data center load demand capture, and which large utility is better positioned for AI power demand.

Compare Exelon and PSEG by nuclear generation portfolio, regulated utility earnings mix, data center power demand exposure, dividend yield, and which Northeast nuclear utility offers better risk-adjusted returns.

Compare Dominion Energy and Southern Company by asset sale transformation, nuclear reliability, regulated earnings growth, dividend reset vs continuation, and which large Southeast utility offers better long-term total return.

Compare DTE Energy and CMS Energy by clean energy transition investment, regulatory relationships in Michigan, non-utility business contribution, EPS growth targets, dividend safety, and which Midwest utility offers better value.

Compare PG&E and Southern Company by wildfire liability resolution, regulatory recovery trajectory, nuclear and renewable generation mix, dividend restoration timeline, and which utility offers better asymmetric upside.

Compare Edison International and American Electric Power by wildfire risk management, EV infrastructure investment, data center load growth, rate base expansion, and which transmission-heavy utility is better positioned for electrification.

Compare American Water Works and York Water by geographic diversification, regulatory rate case success, infrastructure reinvestment yield, dividend growth track record, and whether the premium for AWK's scale is justified.

Compare NextEra and Exelon by renewable energy development pipeline, nuclear fleet earnings leverage, regulated vs unregulated revenue mix, AI data center power demand, and which utility is best positioned for the energy transition.